Upfront riociguat and ambrisentan combination therapy for newly diagnosed pulmonary arterial hypertension: A prospective open-label trialJason Weatherald, Naushad Hirani, Chidera Nwaroh et al.|The Journal of Heart and Lung Transplantation|2022Cited by 12